Dilazep, an Antiplatelet Agent, Inhibits Tissue Factor Expression in Endothelial Cells and Monocytes

By Hiroshi Deguchi, Hiroyuki Takeya, Hideo Wada, Esteban C. Gabazza, Nobuyuki Hayashi, Hajime Urano, and Koji Suzuki

Dilazep, an antiplatelet agent, is generally used as an anti-thrombotic drug in clinical practice. Dilazep is also known to exert cytoprotective and antioxidant effects on endothelial cells. However, its effect on the endothelial or monocyte procoagulant activity is unknown. In the current study, the effect of dilazep on the expression of tissue factor (TF) in human umbilical vein endothelial cells (HUVECs) after the stimulation with tumor necrosis factor-α (TNF), thrombin, or phorbol 12-myristate 13-acetate (PMA) was evaluated. We also evaluated the effect of dilazep on TNF (1,000 U/mL)-induced TF expression on monocytes. Dilazep inhibited TF activity induced on HUVECs by each stimulant, TNF (1,000 U/mL), thrombin (25 nmol/L), or PMA (5 nmol/L) in a dose-dependent fashion (1 to 100 μg/mL). TF activity decreased to approximately 10% after treating with 100 μg/mL of dilazep. Dilazep also blocked the expression of TF antigen induced by each stimulant on the surface of HUVECs as determined by flow cytometric analysis. In addition, in HUVECs, it significantly decreased the expression of TF mRNA and the total TF antigen induced by thrombin or PMA, but not those induced by TNF, suggesting that dilazep blocks the TF expression induced by PMA or thrombin at a transcriptional level and that induced by TNF at a posttranscriptional level. Western blot analysis showed that dilazep reduces the accumulation of native TF but increases that in lower molecular weight TF derivatives. The adenosine receptor antagonist, 8-(p-sulfophenyl)theophylline, partially counteracted the anticoagulant activity of dilazep on HUVECs, thereby suggesting that the inhibitory effect of dilazep on TF expression in HUVECs depends, at least in part, on its adenosine potentiating activity. Dilazep also inhibited TNF-induced TF expression on monocytes in a dose-dependent fashion (0.1 to 100 μg/mL). In brief, the current study showed for the first time that dilazep, a commonly used antiplatelet drug, strongly inhibits the TF expression in HUVECs and monocytes. Dilazep may have a potent therapeutic value in patients with hypercoagulable state for its inhibitory property on the procoagulant activity of endothelial cells and monocytes.

© 1997 by The American Society of Hematology.

MATERIALS AND METHODS

Materials. Citrated human plasma was obtained from the local Red Cross blood center. Human factor VIIa and factor X were provided by Dr Tomohiro Nakagaki (Chemo-Sera Therapeutic Institute, Kumamoto, Japan). Antithrombin, protein C, and thrombin were prepared from human plasma as described. Recombinant human TF was donated by the Asahi Chemical Industry (Fuji, Shizuoka, Japan). The synthetic peptide substrate for factor Xa, N-benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroanilide hydrochloride (S2222), was purchased from Chromogenix (Mölndal, Sweden). The fluorogenic substrate for activated protein C, Boc-Leu-Ser-Thr-Arg-methylcoumarylamide (MCA), was obtained from the Protein Research Foundation (Osaka, Japan). Dulbecco’s phosphate-buffered saline (PBS), gentamycin, bovine serum albumin (BSA), heparin (174 U/mg), and adenosine were from Sigma (St Louis, Missouri).

From the Department of Molecular Pathobiology and the Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie, Japan.

Submitted October 28, 1996; accepted May 16, 1997.

Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (Grants No. 05454622, 06282225, and 06771216) and by Research Aid from Japan Foundation of Cardiovascular Research.

Address reprint requests to Koji Suzuki, PhD, Department of Molecular Pathobiology, Mie University School of Medicine, Edobashi 2-174, Tsu-city, Mie 514, Japan.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.

0006-4971/97/9006-0022$3.00/0

Blood, Vol 90, No 6 (September 15), 1997: pp 2345-2356

2345
Louis, MO). Nick column was obtained from Pharmacia-LKB (Uppsala, Sweden). Triton X-100 and aprotinin were from Boehringer Mannheim GmbH (Mannheim, Germany). Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) cDNA probe and 8-p-sulfophenolyl) theophylline (8-SPT) was purchased from Clontech Labs (Palo Alto, CA) and Research Biochemicals International (Natick, MA), respectively. Horseradish peroxidase (HRP)-conjugated antiserum IgG goat antibody and antigen IgG-rabbit antibody were obtained from Bio-Rad (Richmond, CA). The reagents to check the viability of the cells, WST-1 [2-(4-iiodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium-Na] and 1-methoxy PMS (1-methoxy-5-methyl-phenazinium methylsulphate), were purchased from Dojindo (Kumamoto, Japan).

Patients. Twenty inoperable patients with malignant disease (adenocarcinoma, 12; squamous cell carcinoma, 2; small-cell carcinoma, 2; hepatoma, 2; melanoma, 1; and myeloma, 1) and 8 with benign disorder (dissecting aneurysm of the aorta, 6; chronic enteritis, 1; and chronic viral infection, 1) were studied. All of these patients were in the hypercoagulable state and were treated with dilazep (300 mg/d) for 1 month before the initiation of any kind of therapy. Blood samples were collected from the patients before and after 1 month of starting the therapy with dilazep. Plasma levels of thrombin-antithrombin complex (TAT) and fibrin degradation products (FDP) were determined using Enzygnost-TAT kit (Behringwerke AG, Marburg, Germany; normal range, 1.8 ± 0.7 ng/mL) and Felisa D-dimer (Agen, Brisbane, Australia; normal range, 48 ± 34 ng/mL), respectively. Plasma fibrinogen level was determined using the clotting time method (normal range, 2.5 ± 0.4 mg/mL).

The plasma level of TF antigen was determined by TF enzyme-linked immunosorbent assay (ELISA) kit (Chemo-Sera Therapeutic Institute; normal range, 196.8 ± 54.3 pg/mL). Data are expressed as the mean ± SD. The statistical difference between variables was evaluated by the Student’s t-test or the Wilcoxon rank test according to the Gaussian distribution of the data.

Culture of HUVECs. HUVECs were purchased from Kurabo (Osaka, Japan). The cells were cultured in modified MCD medium (Chlorella Industry, Tokyo, Japan) supplemented with 2% fetal bovine serum (GIBCO BRL, Grand Island, NY), 50 µg/mL gentamicin, 0.01 µg/mL epidermal growth factor (Becton Dickinson, Bedford, MA), 10 µg/mL endothelial cell growth factor (Becton Dickinson), and 10 µg/mL unfractionated heparin (Sigma) under an atmosphere of 95% air and 5% CO2.

Preparation of peripheral blood mononuclear cells. Peripheral blood cells were obtained from healthy donors by vein puncture using EDTA as anticoagulant. Mononuclear cells were isolated by the Lymphoprep tube (Nycomed Pharma Diagnostica, Oslo, Norway). The mononuclear cell phase, comprising monocytes and lymphocytes, was harvested, washed twice with RPMI (RPMI 1640 medium supplemented with 2 mM L-Glutamine, 100 µg/mL streptomycin, 100 µg/mL penicillin, 10% fetal bovine serum), and resuspended in RPMI.

Determination of HUVEC surface TF activity. TF activity was determined as factor X activation by factor VIIa/TF complex on HUVECs after stimulation with TNF, thrombin, or PMA. After incubation of the cells (24-well plate, 5 × 105 cells/well) with each membrane was then incubated with a 1/20,000 dilution of antigoat antibody and antigoat IgG-rabbit antibody were obtained from Jackson ImmunoResearch Laboratories, West Grove, PA, and Research Biochemicals International (Natick, MA), respectively. The cells were then washed three times with PBS. The cells were then incubated with the F(ab')2 fraction of a fluorescein isothiocyanate (FITC)-labeled antigoat IgG antibody (1/20 dilution) for 30 minutes at 4°C. The cells were then washed three times with PBS and fixed in fluorescence-activated cell sorting (FACS) lysing solution (Becton Dickinson) according to the manufacturer’s instructions. Flow cytometric analysis was performed using a FACScan analyzer (Becton Dickinson) equipped with a 15-mW, 488-nm argon-ion laser. Green fluorescence emission was recorded at 530 nm. A total of 10,000 events were analyzed per sample. Median channel fluorescence in each sample was determined using a logarithmic scale. Logarithmic channel was converted into linear channel fluorescence units to facilitate comparison of results.

Measurement of total TF antigen level in HUVECs. The total cell TF antigen levels in lysates of HUVECs were measured by ELISA. Briefly, after stimulation of HUVECs with TNF, thrombin, or PMA in the presence or absence of dilazep, the cells were washed twice with cold Dulbecco’s PBS and harvested. Subsequently, harvested cells were centrifuged (2,000 rpm for 5 minutes) and the precipitate was dissolved in Tris-buffered saline (TBS; 50 mM Tris/HCl, 150 mM NaCl, pH 7.5) containing, 0.6% (w/v) Triton X-100 and aprotinin (100 µg/mL). The cellular extraction was then diluted 1,000-fold with TBS containing 0.1% BSA and 0.02% thimerosal and applied to wells coated with rabbit antihuman TF antibodies (American Diagnostica, Greenwich, CT). The wells were blocked with 100 mM phosphate buffer, pH 8.0, containing 5% BSA, and then washed three times with TBS containing 0.1% BSA and 0.02% thimerosal. Then, biotinyl-monoclonal antibody against human TF (MSTF-3) was added and incubated for 2 hours. After washing the wells, HRP-labeled streptavidin was added and incubated for 1 hour. After the addition of H2O2 and peroxidase substrate, color development was measured at 492 nm using an EAR microplate reader.

Western blotting analysis of TF antigen in HUVECs. TF expression in HUVECs was determined by Western blotting using polyclonal goat antihuman TF antibodies (American Diagnostica). Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of HUVEC lysates was performed, followed by blotting onto nitrocellulose membrane. The membrane was incubated with blocking solution (100 mM/L PBS, pH 7.5, containing 5% BSA and 0.5% Tween 20) and then exposed to a 1/20,000 dilution of goat anti-TF antibodies for 1 hour while shaking at room temperature. After washing the membrane with PBS containing 0.1% BSA and 0.5% Tween 20, the membrane was then incubated with a 1/20,000 dilution of goat IgG antibody conjugated to HRP. The membrane was washed and quantitated using an enhanced chemiluminescence detection system (ECL, Amersham, Buckinghamshire, UK) as described previously.

Analysis of TF mRNA with reverse transcription and polymerase chain reaction (RT-PCR). Total RNA of HUVECs was prepared using the RNA zol (Cinna/Biotex Laboratories, Houston, TX) after incubating the cells with TNF, thrombin, or PMA in the presence or absence of dilazep. RT-PCR was performed as described previously. Briefly, total RNA (1 µg) was reverse transcribed by superscript prem amplification system (GIBCO BRL) with random after incubating for 20 minutes at room temperature. The reaction was stopped by the addition of 10 µL of 20% acetic acid, and color development was determined by measuring the absorbance at 405 nm with an EAR 340 microplate reader (SLT-Lab Instruments, Salzburg, Austria).
Bio-Image analyzer (Fuji Photo Film, Tokyo, Japan). The amount of Clotting was initiated by the addition of 50 mM 0.1% BSA and 5 mmol/L CaCl₂. Effect of dilazep in patients with hypercoagulable state. Twenty-eight patients with hypercoagulable state were treated with dilazep (300 mg/d) for 1 month. Plasma levels of TAT, FDP-D-dimer, fibrinogen, and TF antigen were determined by ELISA or the clotting time method before and after treatment with dilazep as described in the Materials and Methods. Values are expressed as the mean ± SD. *P < .001.

Effect of dilazep in patients with hypercoagulable state. We evaluated the effect of dilazep on hemostatic markers in patients with hypercoagulable state. The plasma levels of TAT (32.3 ± 19.7 ng/mL), FDP-D-dimer (1.411.1 ± 384.4 v 617.6 ± 127.3 ng/mL), fibrinogen (4.1 ± 0.4 v 3.1 ± 0.3 mg/mL), and TF antigen (355.5 ± 94.0 v 234.9 ± 62.2 pg/mL) significantly (P < .001) decreased after treatment with dilazep (300 mg/d), as shown in Fig 1.
These hemostatic parameters also decreased significantly in each patient group (malignant and benign disease) after treatment with dilazep ($P < .001$) as compared with baseline values (data not shown). This finding suggests that dilazep has a potent anticoagulant activity on endothelial cells or intravascular leukocytes. This preliminary clinical study prompted us to evaluate the effect of dilazep on endothelial cell procoagulant activity.

**Effect of dilazep on TF activity of HUVECs stimulated with TNF, thrombin, or PMA.** We evaluated the effect of dilazep on TF expression in HUVECs stimulated with the inflammatory mediators TNF, thrombin, or PMA. A gradual increase in TF activity was observed on HUVECs after stimulating with TNF, thrombin, or PMA, reaching a maximum level after 5 to 6 hours. As shown in Fig 2, 100 μg/mL dilazep inhibited this stimulatory effect of TNF, thrombin, or PMA on TF activity of HUVECs. TF activity on stimulated HUVECs for 5 hours depended on the dose of the stimulant as described previously, and the activity reached maximal levels at concentrations of 1,000 U/mL TNF, 25 nmol/L thrombin, and 5 nmol/L PMA, respectively. Coincubation with 100 μg/mL dilazep decreased approximately 90% of the TF activity induced by each stimulant (Fig 3). Increasing concentrations of dilazep (0 to 100 μg/mL) decreased the cell surface TF activity in a dose-dependent fashion (Fig 4).

The minimal concentration of dilazep required for inhibiting the TNF-stimulated TF expression was 1 μg/mL, but that for the thrombin- and PMA-stimulated TF expression was 0.1 μg/mL. The concentrations of dilazep required for 50% inhibition of the expression of TF activity on HUVECs induced by 1,000 U/mL TNF, 25 nmol/L thrombin, and 5 nmol/L PMA were approximately 20, 2.5, and 20 μg/mL, respectively.

---

**Fig 2.** Time course of TF activity expression on HUVECs stimulated with TNF, thrombin, or PMA and the effect of dilazep on the TF expression. HUVECs ($5 \times 10^5$/well) were stimulated with (A) 1,000 U/mL TNF, (B) 25 nmol/L thrombin, or (C) 5 nmol/L PMA in the presence (●) or absence (○) of $100 \mu g/mL$ dilazep. The TF activity on HUVEC surface was determined at 0, 3, 5, 6, 9, 12, and 24 hours after incubation with each stimulant as factor Xa generation ($A_{405nm}$/20 minutes) using S2222 (see the Materials and Methods). The values represent the mean ± SD of four independent experiments.

**Fig 3.** The effect of dilazep on TF activity on HUVECs stimulated with varying concentrations of TNF, thrombin, or PMA. HUVECs were treated for 5 hours with varying concentrations of each stimulant. (A) TNF (0 to 2,500 U/mL), (B) thrombin (0 to 250 U/mL), and (C) PMA (0 to 250 nmol/L) in the presence (●) or absence (○) of $100 \mu g/mL$ dilazep. TF activity on HUVEC surface was determined as factor Xa generation ($A_{405nm}$/20 minutes) using S2222 (see the Materials and Methods). The values represent the mean ± SD of four independent experiments.
The values represent the mean ± SD of four independent experiments.
Effect of adenosine on the TF activity of HUVECs stimulated with TNF, thrombin, or PMA. Increasing concentrations of adenosine (0 to 10 μmol/L) decreased the TF activity expression on the surface of HUVECs stimulated with 1,000 U/mL TNF, 25 nmol/L thrombin, or 5 nmol/L PMA in a dose-dependent fashion (Fig 10). Coincubation with 10 μmol/L adenosine decreased approximately 50% the TF activity on HUVECs induced by each stimulant. These findings indicate that adenosine significantly blocks the TF expression in HUVECs stimulated with TNF, thrombin, or PMA. Viability of HUVECs as determined using WST-1 was not affected by adenosine at any concentration used in this experiment.

Additive effect of dilazep and adenosine on the TF activity of HUVECs stimulated with TNF, thrombin, or PMA. Isotope-technical studies using ³H-dilazep in humans showed that the therapeutic concentration of dilazep in the systemic circulation is around 1 μg/mL. The therapeutic concentration of dilazep is known to increase the concentration of adenosine in the extracellular space fluid up to micromolar levels. In our assays, we used a dose of dilazep equal to its therapeutic blood concentration in combination with adenosine. We found that dilazep, in combination with adenosine, inhibited the 1,000 U/mL TNF- and 25 nmol/L thrombin-induced TF expression in HUVECs more significantly (60%) than dilazep alone, as shown in Fig 11.

Effect of dilazep on TF activity of monocytes stimulated with TNF. Peripheral blood monocytes are known to participate in blood coagulation processes by expressing TF after being stimulated with inflammatory mediators.
DILAZEP INHIBITS TF EXPRESSION IN HUVECS

Viability of mononuclear cells as determined by using WST-1 and 1-methoxy PMS was not affected by dilazep at any concentration used in this experiment.

**DISCUSSION**

Various cytokines, such as TNF, IL-1, and lymphotoxin, play relevant roles in several inflammatory processes and in the pathogenesis of atherosclerosis. Activation of endothelial cells by these mediators induces the expression of TF that converts the quiescent endothelium into a procoagulant surface. Increased thrombin generation at sites of vascular injury is believed to play a critical role in the pathogenesis of atherosclerosis. Antiplatelet therapy is commonly used in patients at risk of developing thrombotic disease. Dilazep is one of the antiplatelet drugs commonly used in European countries and Japan. Dilazep exerts antiplatelet activity by increasing the extracellular fluid level of adenosine in the systemic circulation by blocking adenosine uptake. Dilazep is also known to dilate coronary, cerebral, and renal vessels by blocking the calcium influx and to prevent the occurrence of thrombus formation in experimental animals.

In preliminary clinical studies, we found that dilazep decreases the plasma level of various hemostatic markers (TAT, FDP-D-dimer, and fibrinogen) in patients with hypercoagulable state. Dilazep was also found to decrease the level of plasma TF antigen that is known to be a marker of endothelial cell or leukocyte activation. These findings prompted us to investigate the effect of dilazep on the procoagulant activity of HUVECs stimulated with TNF, thrombin, or PMA. The results of the present study showed that dilazep significantly inhibits the expression of TF in HUVECs and monocytes.

TF expression is known to be regulated at both transcriptional and posttranscriptional levels. In the current study, analysis of the TF mRNA expression showed that the thrombin- or PMA-induced TF expression in HUVECs is blocked by dilazep probably due to an effect on TF gene transcription and/or TF mRNA stability. PMA and thrombin are well-known activators of protein kinase C. This can be activated directly by PMA or indirectly by thrombin via the G protein-coupled receptor. Thus, dilazep probably...
The effect of dilazep on TF mRNA expression in HUVECs stimulated with TNF, thrombin, or PMA. (A) HUVECs were stimulated with each stimulant: 1,000 U/mL TNF, 25 nmol/L thrombin, or 5 nmol/L PMA for 3 hours in the presence (+) or absence (−) of 100 μg/mL dilazep. TF mRNA expression was analyzed using the RT-PCR method as described in the Materials and Methods. The amplified cDNA was blotted onto a nitrocellulose membrane and hybridized with the [32P]TF cDNA probe and then analyzed using an autoradiogram. (B) The data in (A) are depicted after normalization to equal amount of RNA loads based on the intensity of GAPDH mRNA. The data are expressed as the percentage of the control (each stimulant induced TF mRNA in the absence of dilazep). The values represent the mean ± SD of four independent experiments. Statistical analysis was performed using the Student’s t-test (*P < .05).

Inhibits the PMA- or thrombin-induced TF mRNA expression by blocking the protein kinase C-mediated signaling pathway. On the contrary, dilazep inhibited the HUVEC surface TF expression but it did not inhibit the expressions of total TF antigen and TF mRNA induced by TNF in HUVECs. This latter finding may be explained by the different signaling pathway of TNF-induced TF expression from that of thrombin- or PMA-induced TF expression. In this regard, TNF was previously found to induce TF mRNA expression in HUVECs by the sphingomyelinase/ceramide pathway.42
DILAZEP INHIBITS TF EXPRESSION IN HUVECS

Fig 9. Effect of 8-SPT on the dilazep-induced downregulation of TF activity on the surface of HUVECs stimulated with TNF, thrombin, or PMA. HUVECs (2 x 10⁶ cells/well) were incubated with (1 mmol/L, final concentration; □) or without (■) 8-SPT for 15 minutes and then with 100 µg/mL dilazep. After incubation of the cells with 1,000 U/mL TNF, 25 mmol/L thrombin, or 5 mmol/L PMA, in the presence or absence of dilazep, the cells were washed twice with 1 mL of HEPES-buffered saline containing 5 mmol/L CaCl₂. TF activity was determined as factor Xa generation on the surface of HUVECs as described in the Materials and Methods. The data are expressed as the percentage of the control (each stimulant induced TF activity in the absence of dilazep). Statistical analysis was performed using the Student’s t-test (*P < .05; **P < .001).

Fig 10. The effect of varying concentrations of adenosine on TF activity expression on HUVECs stimulated with TNF, thrombin, or PMA. HUVECs were treated for 5 hours with each stimulant: 1,000 U/mL TNF (□), 25 mmol/L thrombin (■), or 5 mmol/L PMA (▲) in the presence of varying concentrations of adenosine (0, 2.5, 5, and 10 µmol/L). TF activity on HUVEC surface was determined as factor Xa generation using S2222 (see the Materials and Methods). The data are expressed as the percentage of the control (each stimulant induced TF activity in the absence of adenosine). The values represent the mean ± SD of four independent experiments. Statistical analysis was performed using the Student’s t-test (*P < .05; **P < .001).

Fig 11. Additive effect of dilazep and adenosine on the TF activity of HUVECs stimulated with TNF, thrombin, or PMA. HUVECs (2 x 10⁶ cells/well) were incubated with (1 µg/mL, final concentration) or without adenosine for 15 minutes and then with adenosine (2.5 µmol/L). After incubation of the cells with 1,000 U/mL TNF, 25 mmol/L thrombin, or 5 mmol/L PMA, in the presence or absence of dilazep or adenosine, the cells were washed twice with 1 mL of HEPES-buffered saline containing 5 mmol/L CaCl₂. TF activity was determined as factor Xa generation on the surface of HUVECs as described in the Materials and Methods. The data are expressed as the percentage of the control (each stimulant induced TF activity in the absence of both dilazep and adenosine). Statistical analysis was performed using the Student’s t-test (*P < .05; **P < .005; ***P < .001).

In addition, TNF-mediated activation of protein kinase C is in general not required for nuclear factor-κB activation or for protein expression in endothelial cells. On the other hand, the fact that dilazep inhibited HUVEC surface expression of TF (decrease in TF activity and in its surface antigen expression by factor Xa generation assay and FACScan, respectively) without blocking the expression of total TF antigen and TF mRNA in these cells, as measured by ELISA and RT-PCR, suggests that dilazep regulated TNF-induced TF surface expression at the posttranscriptional level. Alteration in the folding, processing, and translocation of TF may be the potential mechanisms by which dilazep exerts this effect. Another piece of evidence that suggests the posttranscriptional regulation of TNF-induced TF expression by HUVECs is the results of the Western blot analysis showing that dilazep reduced the accumulation of matured forms (47 kD) of TF but increased the formation of TF with lower molecular weight (33 kD) in TNF-treated HUVECs. Similar lower molecular weight TF formation has been previously reported in lipopolysaccharide-treated mononuclear cells by endogenous cellular antioxidant potentiation. Dilazep is also known to act as an antioxidant agent and to modulate cytoplasmic redox state on endothelial cells. The redox state regulates protein synthesis at posttranscriptional level.
by altering the stability and the translation rate of mRNA or by modifying protein folding or glycosylation. The antioxidant activity of dilazep might generate reduced conditions in cytoplasm resulting in unstable/immatured forms of TF. Thus, it is conceivable that dilazep inhibits the transport of TF to the cell surface by affecting the formation of matured forms of the protein in TNF-stimulated HUVECs. Another point that needs clarification is the mechanism by which dilazep activates the signaling pathway of HUVECs for the transcriptional or posttranscriptional regulation of TF. Dilazep was previously reported to inhibit adenosine uptake by endothelial cells leading to increased plasma adenosine levels. In the current study, we evaluated whether this adenosine potentiating activity of dilazep downregulates TF expression in HUVECs. The inhibitory effect of dilazep on TF expression in HUVECs stimulated with TNF, thrombin, or PMA was counteracted by adenosine receptor antagonists, suggesting that the inhibitory effect of dilazep is mediated, at least in part, by adenosine receptors. Adenosine itself was also found to inhibit TF expression in HUVECs. All together, these findings suggest that adenosine and its receptor might play important roles in the regulation of TF expression on endothelial cells.

Our present study showed that dilazep (300 mg/d) dramatically decreases various hemostatic markers and that it significantly inhibits the TF expression induced by inflammatory agents in endothelial cells. These results suggest that dilazep may act as an anticoagulant agent in vivo besides its antiplatelet and vasodilator activities. The therapeutic blood concentration of dilazep was reported to be around 1 

\[
\text{REFERENCES}
\]

8. Herbert JM, Savi P, Laplace MC, Lale A: IL-4 inhibits...
DILAZEP INHIBITS TF EXPRESSION IN HUVECS


Dilazep, an Antiplatelet Agent, Inhibits Tissue Factor Expression in Endothelial Cells and Monocytes

Hiroshi Deguchi, Hiroyuki Takeya, Hideo Wada, Esteban C. Gabazza, Nobuyuki Hayashi, Hajime Urano and Koji Suzuki